Uniwersytecki Szpital Kliniczny W Poznaniu
- Address
- lock Available on a paid plan
Oncology and Neoplasms
At Uniwersytecki Szpital Kliniczny W Poznaniu, clinical research is focused on cancer care, with studies centered on melanoma. The trials are designed to help prevent disease return after surgery and to evaluate new ways of delivering treatment for advanced disease.
- Completely resected Stage IIb/c melanoma
- Previously untreated metastatic or unresectable melanoma
- Testing treatment effectiveness and comparing delivery methods for immunotherapy
These studies reflect a strong interest in improving outcomes for people with melanoma, from reducing recurrence risk to exploring more convenient and potentially effective treatment options.
Melanoma Immunotherapy Research
This research program in Poznan examines immunotherapy for melanoma, including both earlier-stage disease after complete surgery and more advanced cases that have not yet been treated. The goal is to assess how well these approaches work and whether alternative administration routes can support patient care.
- Recurrence prevention after complete resection of Stage IIB/C melanoma
- Advanced metastatic or unresectable melanoma
- Evaluating clinical benefit and treatment delivery options
The site’s activity in oncology highlights a focused effort to advance therapies that may improve both disease control and treatment experience for patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 19 therapeutic areas and 15 of 294 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 284 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 70 by active trials.
- 1AstraZeneca AB10active
lock +69 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC25trials
lock +33 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Uniwersytecki Szpital Kliniczny W Poznaniu
lock Showing 1 of 244 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22419) A randomized, double-blind, placebo-controlled, parallel group Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome | Bayer AG | Phase II | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 294 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 32 | Unknown | 2016-02-02 | 2026-04-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.